Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIstanbul University - Cerrahpasa

About this trial

The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening.

Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.

Eligibility criteria

Qualifiers

Adults aged 18 years or older

Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines

Followed at the study center with a diagnosis of PAH

Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval

Disqualifiers

Age younger than 18 years

Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)

Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval

Incomplete clinical or imaging data preventing analysis

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

50 Participants
are grouped into 1 trial group